Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 273-279 , August 2007

Corticosteroids in perinatal medicine: How to improve outcomes without affecting the developing brain?

  • Olivier Baud

      Affiliations

    • NICU and Neonatal Medicine, INSERM U676, Robert Debré Children's Hospital, 48 Bd Sérurier, 75019 Paris, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 4003 2456; fax: +33 1 4003 2470.
    • ,
  • Augusto Sola

      Affiliations

    • Mid-Atlantic Neonatology Associates and Morristown Memorial Hospital, Morristown, NJ, USA

References 

  1. Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infant. Pediatrics. 1972;50:515–525
  2. Crowley P. Prophylactic corticosteroids for preterm delivery [review]. In: The Cochrane Library. The Cochrane Collaboration. Oxford, Engl: Update software; Issue 3, 1999.
  3. National Institutes of Health . Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Statement. 1994;12:1–24
  4. Leviton A, Dammann O, Allred EN, Kuban K, Pagano M, Van Marter L, et al. Antenatal corticosteroids and cranial ultrasonographic abnormalities. Am J Obstet Gynecol. 1999;181:1007–1017
  5. Pagano M, Leviton A, Kuban K. Early and late germinal matrix hemorrhage may have different antecedents. Eur J Obstet Gynecol Reprod Biol. 1990;37:47–54
  6. O'Shea M, Davitz DA, Hage ML, Feinstein KA. Prenatal events and the risk of subependymal/intraventricular haemorrhage in very low birthweight neonates. Paediatr Perinat Epidemiol. 1992;6:352–362
  7. Garland JS, Buck R, Leviton A. Effect of maternal glucocorticoid exposure on risk of severe intraventricular hemorrhage in surfactant-treated preterm infants. J Pediatr. 1995;126:272–279
  8. White A, Marcucci G, Andrews E, Edwards K, Long W. Antenatal steroids and neonatal outcomes in controlled clinical trials of surfactant replacement. The American Exosurf Neonatal Study Group I and The Canadian Exosurf Neonatal Study Group. Am J Obstet Gynecol. 1995;173:286–290
  9. Shankaran S, Bauer CR, Bain R, Wright LL, Zachary J. Relationships between antenatal steroid administration and grade III and IV intracranial hemorrhage in low birth weight infants. The NICHD Neonatal Research Network. Am J Obstet Gynecol. 1995;173:305–312
  10. Palta M, Sadek M, Gabbert D, Brady W, Weinstein MR, McGuinness G, et al. The relation of maternal complications to outcomes in very low birthweight infants in an era of changing neonatal care. Am J Perinatol. 1996;13:109–114
  11. Chen B, Basil JB, Schefft GL, Cole FS, Sadovsky Y. Antenatal steroids and intraventricular hemorrhage after premature rupture of membranes at 24–28weeks'gestation. Am J Perinatol. 1997;14:171–176
  12. Verma U, Tejani N, Klein S, Reale MR, Beneck D, Figueroa R, et al. Obstetric antecedents of intraventricular hemorrhage and periventricular leukomalacia in the low-birth-weight neonate. Am J Obstet Gynecol. 1997;176:275–281
  13. O'Shea TM, Kothadia M, Roberts DD, Dillard RG. Perinatal events and the risk of intraparenchymalechodensity in very-low-birthweight neonates. Paediatr Perinat Epidemiol. 1998;12:408–421
  14. Elimian A, Verma U, Canterino J, Shah J, Visintainer P, Tejani N. Effectiveness of antenatal steroids in obstetric subgroups. Obstet Gynecol. 1999;93:174–179
  15. Baud O, Zupan V, Lacaze-Masmonteil T, Audibert F, Shojaei T, Thebaud B, et al. The relationship between antenatal management, the cause of delivery and neonatal outcome in a large cohort of very preterm singleton infants. BJOG. 2000;107:877–884
  16. Leviton A, Pagano M, Kuban KC. Etiologic heterogeneity of intracranial hemorrhages in preterm newborns. Pediatr Neurol. 1988;4:274–278
  17. Baud O, Foix-L'Helias L, Kaminski M, Audibert F, Jarreau PH, Papiernik E, et al. Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med. 1999;341:1190–1196
  18. Harding JE, Pang J, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes?. Am J Obstet Gynecol. 2001;184:131–139
  19. Schmand B, Neuvel J, Smolders-de Haas H, Hoeks J, Treffers PE, Koppe JG. Psychological development of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome. Pediatrics. 1990;86:58–64
  20. Collaborative Group on Antenatal Steroid Therapy . Effects of antenatal dexamethasone administration in the infant: long-term follow-up. J Pediatr. 1984;104:259–267
  21. Salokorpi T, Sajaniemi N, Hallback H, Kari A, Rita H, von Wendt L. Randomized study of the effect of antenatal dexamethasone on growth and development of premature children at the corrected age of 2years. Acta Paediatr. 1997;86:294–298
  22. Dessens AB, Haas HS, Koppe JG. Twenty-year follow-up of antenatal corticosteroid treatment. Pediatrics. 2000;105:E77
  23. Arad I, Durkin MS, Hinton VJ, Kuhn L, Chiriboga C, Kuban K, et al. Long-term cognitive benefits of antenatal corticosteroids for prematurely born children with cranial ultrasound abnormalities. Am J Obstet Gynecol. 2002;186:818–825
  24. Lipworth BJ. Therapeutic implications of non-genomic glucocorticoid activity. Lancet. 2000;356:87–89
  25. Crowley P. Antenatal corticosteroid therapy: a meta-analysis of the randomised trials, 1972–1994. Am J Obstet Gynecol. 1995;173:322–335
  26. Ballard PL, Ballard RA. Scientific basis and therapeutic regimes for use of antenatal glucocorticoids. Am J Obstet Gynecol. 1995;173:254–262
  27. Henson G. Antenatal corticosteroids and heart rate variability. Br J Obstet Gynaecol. 1997;104:1219–1220
  28. Christensen HD, Sienko AE, Rayburn WF, Gonzalez CL, Coleman FH. A placebo-controlled, blinded comparison between betamethasone and dexamethasone to enhance lung maturation in the fetal mouse. J Soc Gynecol Invest. 1997;4:130–134
  29. Rayburn WF, Christensen HD, Gonzalez CL. A placebo-controlled comparison between betamethasone and dexamethasone for fetal maturation: Differences in neurobehavioral development of mice offspring. Am J Obstet Gynaecol. 1997;176:842–851
  30. Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol. 2004;190:878–881
  31. Lee BH, Stoll BJ, McDonald SA, Higgins RD. National Institute of Child Health and Human Development Neonatal Research Network. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics. 2006;117:1503–1510
  32. Baud O, Laudenbach V, Evrard P, Gressens P. Neurotoxic effects of fluorinated glucocorticoids preparations on the developing mouse brain: role of preservatives. Pediatr Res. 2001;50:706–711
  33. Magee LA, Dawes GS, Moulden M, Redman CW. A randomised controlled comparison of betamethasone with dexamethasone: effects on the antenatal fetal heart rate. Br J Obstet Gynaecol. 1997;104:1233–1238
  34. Multon O, Senat MV, Minoui S, Hue MV, Frydman R, Ville Y. Effect of antenatal betamethasone and dexamethasone administration on fetal heart variability in growth-retarded fetuses. Fetal Diagn Ther. 1997;12:170–177
  35. McGowan JE, Sysyn G, Petersson KH, et al. Effect of dexamethasone treatment on maturational changes in the NMDA receptor in sheep brain. J Neurosci. 2000;20:7424–7429
  36. Planer BC. Use of antenatal corticosteroids in USA (ABST 576). Am J Obstet Gynecol. 1996;174:467
  37. Elimian A, Verma U, Visintainer P, Tejani N. Effectiveness of multidose antenatal steroids. Obstet Gynecol. 2000;95:34–36
  38. Banks BA, Cnaan A, Morgan MA, et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol. 1999;181:709–717
  39. Pratt L, Waschbusch L, Ladd W, Gangnon R, Hendricks SK. Multiple vs. single betamethasone therapy. Neonatal and maternal effects. J Reprod Med. 1999;44:257–264
  40. Jobe AH, Wada N, Berry LM, Ikegami M, Ervin MG. Single and repetitive maternal glucocorticoid exposures reduce fetal growth in sheep. Am J Obstet Gynecol. 1998;178:880–885
  41. Abbasi S, Hirsch D, Davis J, Tolosa J, Stouffer N, Debbs R, et al. Effect of single versus multiple courses of antenatal corticosteroids on maternal and neonatal outcome. Am J Obstet Gynecol. 2000;182:1243–1249
  42. Ikegami M, Jobe AH, Newnham J, Polk DH, Willet KE, Sly P. Repetitive prenatal glucocorticoids improve lung function and decrease growth in preterm lambs. Am J Respir Crit Care Med. 1997;156:178–184
  43. Aghajafari F, Murphy K, Matthews S, Ohlsson A, Amankwah K, Hannah M. Repeated doses of antenatal corticosteroids in animals: a systematic review. Am J Obstet Gynecol. 2002;186:843–849
  44. Guinn DA, Atkinson MW, Sullivan L, Lee M, MacGregor S, Parilla BV, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA. 2001;286:1581–1587
  45. Wapner RJ, Sorokin Y, Thom EA, Johnson F, Dudley DJ, Spong CY, et al. Single versus weekly courses of antenatal corticosteroids: evaluation of safety and efficacy. Am J Obstet Gynecol. 2006;195:633–642
  46. Crowther D, Wilkinson T, Biddulph P, Oreszczyn T, Pretlove S, Ridley I. Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial. Lancet. 2006;367:1913–1919
  47. Modi N, Lewis H, Al-Naqeeb N, Ajayi-Obe M, Dore CJ, Rutherford M. The effects of repeated antenatal glucocorticoid therapy on the developing brain. Pediatr Res. 2001;50:581–585
  48. French NP, Hagan R, Evans SF, Godfrey M, Newnham JP. Repeated antenatal corticosteroids: size at birth and subsequent development. Am J Obstet Gynecol. 1999;180:114–121
  49. French NP, Hagan R, Evans SF, Mullan A, Newnham JP. Repeated antenatal corticosteroids: effects on cerebral palsy and childhood behavior. Am J Obstet Gynecol. 2004;190:588–595
  50. Doyle LW, Ford GW, Davis NM, Callanan C. Antenatal corticosteroid therapy and blood pressure at 14years of age in preterm children. Clin Sci. 2000;98:137–142
  51. Dalziel SR, Liang A, Parag V, Rodgers A, Harding JE. Blood pressure at 6years of age after prenatal exposure to betamethasone: follow-up results of a randomized, controlled trial. Pediatrics. 2004;114:e373–e377
  52. Dalziel SR, Walker NK, Parag V, Mantell C, Rea HH, Rodgers A, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet. 2005;365:1856–1862
  53. Mammel MC, Green TP, Johnson DE, Thompson TR. Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet. 1983;1:1356–1358
  54. Avery GB, Fletcher AB, Kaplan M, Brudno DS. Controlled trial of dexamethasone in respirator dependent infants with bronchopulmonary dysplasia. Pediatrics. 1985;75:106–111
  55. Bhuta T, Ohlsson A. Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch Dis Child Fetal Neonatal Ed. 1998;79:F26–F33
  56. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate. 1999;76(Suppl. 1):29–40
  57. Finer NN, Craft A, Vaucher YE, Clark RH, Sola A. Postnatal steroids: short-term gain, long-term pain?. J Pediatr. 2000;137:9–13
  58. Jobe AH. Glucocorticoids in perinatal medicine: misguided rockets?. J Pediatr. 2000;137:1–3
  59. Gressens P, Mesples B, Sahir N, Marret S, Sola A. Environmental factors and disturbances of brain development. Semin Neonatol. 2001;6:185–194
  60. Gressens P, Rogido M, Paindaveine B, Sola A. The impact of neonatal intensive care practices on the developing brain. J Pediatr. 2002;140:646–653
  61. Larroque B, Samain H. Groupe Epipage. Epipage study: mortality of very premature infants and state of progress at follow up. J Gynecol Obstet Biol Reprod. 2001;30:S33–S41
  62. Lee SK, McMillan DD, Ohlsson A, et al. Variations in practice and outcomes in the Canadian NICU Network: 1996–1997. Pediatrics. 2000;106:1070–1079
  63. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, et al. Very low birth weight outcomes of the National Institutes of Child Health and Human Development Neonatal Research Network, January 1995 through December 1996. Pediatrics. 2001;107:e1
  64. Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev. 1998;53:81–94
  65. Ueda K, Cho K, Matsuda T, Okajima S, Uchida M, Kobayashi Y, et al. A rat model for arrest of alveolarization induced by antenatal endotoxin administration. Pediatr Res. 2006;59:396–400
  66. Halliday HL, Ehrenkranz RA. Early postnatal (<96hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001146
  67. Halliday HL, Ehrenkranz RA. Moderately early (7–14days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001144
  68. Halliday HL, Ehrenkranz RA. Delayed (>3weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2003;(1):CD001145
  69. Yeh TF, Lin YJ, Huang CC, Chen YJ, Lin CH, Lin HC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics. 1998;101:e7
  70. Shinwell ES, Karplus M, Reich D, Weintraub Z, Blazer S, Bader D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed. 2000;83:F177–F181
  71. O'Shea TM, Kothadia JM, Klinepeter KL, Goldstein DJ, Jackson BG, Weaver RG, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics. 1999;104:15–21
  72. Baud O. Is perinatal dexamethasone treatment safe in preterm infants?. Dev Med Child Neurol. 2001;86(Suppl.):23–25
  73. Barrington KJ. The adverse neuro-developmental effects of postnatal steroids in the preterm infant: a systematic review of RCTs. BMC Pediatr. 2001;1:1
  74. Halliday HL. Early postnatal dexamethasone and cerebral palsy. Pediatrics. 2002;109:1168–1169
  75. Bos AF, Martijn A, van Asperen RM, Hadders-Algra M, Okken A, Prechtl HF. Qualitative assessment of general movements in high-risk preterm infants with chronic lung disease requiring dexamethasone therapy. J Pediatr. 1998;132:300–306
  76. Yeh TF, Lin YJ, Lin HC, Huang CC, Hsieh WS, Lin CH, et al. Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity. N Engl J Med. 2004 Mar 25;350(13):1304–1313
  77. Murphy BP, Inder TE, Huppi PS, Warfield S, Zientara GP, Kikinis R, et al. Impaired cerebral cortical gray matter growth after treatment with dexamethasone for neonatal chronic lung disease. Pediatrics. 2001;107:217–221
  78. Riva MA, Fumagalli F, Racagni G. Opposite regulation of basic fibroblast growth factor and nerve growth factor gene expression in rat cortical astrocytes following dexamethasone administration. J Neurochem. 1995;64:2526–2533
  79. Kauffman F, Seidler FJ, Slotkin TA. Prenatal dexamethasone exposure causes loss of neonatal hypoxia tolerance: cellular mechanisms. Pediatr Res. 1994;35:515–522
  80. Tombaugh GC, Yang SH, Swanson RA, Sapolsky RM. Glucocorticoids exacerbate hypoxic and hypoglycaemic hippocampal injury in vitro. J Neurochem. 1992;59:137–146
  81. Prodanov D, Mantchev G, Iliev A, Traykov V, Yakimova K, Kaneva R, et al. Effects of dexamethasone in rat neonatal model of axotomy-induced motoneuronal cell death. Arch Physiol Biochem. 1998;106:355–361
  82. Tsubota S, Adachi N, Chen J, Yorozuya T, Nagaro T, Arai T. Dexamethasone changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats. Anesthesiology. 1999;90:515–523
  83. Tuor UI, Chuman PD, Del Bigio MR. Prevention of hypoxic-ischaemic damage with dexamethasone is dependent on age and not influenced by fasting. Exp Neurol. 1995;132:116–122
  84. Flavin MP. Influence of dexamethasone on neurotoxicity caused by oxygen and glucose deprivation in vitro. Exp Neurol. 1996;139:34–38
  85. Arquie C, Leroux P, Bodenant C, Laquerriere A, Marpeau L, Marret S. Glucocorticoid treatment in an ischaemic-like excitotoxic model of periventricular leucomalacia in mice. Br J Obstet Gynaecol. 2002;109:989–996
  86. Arquie C, Leroux P, Bodenant C, Leroux P, Dommergues MA, Evrard P, et al. Central role of microglia in neonatal excitotoxic lesions of the murine periventricular white matter. Brain Pathol. 2001;11:56–71
  87. Marret S, Gressens P, Evrard P. Arrest of neuronal migration by excitatory amino acids in hamster developing brain. Proc Natl Acad Sci USA. 1996;93:15463–15468
  88. Schwab M, Antonow-Schlorke I, Kuhn B, et al. Effect of antenatal betamethasone treatment on microtubule-associated proteins MAP1B and MAP2 in fetal sheep. J Physiol. 2001;530:497–506
  89. Weichsel ME. The therapeutic use of glucocorticoid hormones in the perinatal period. Potential neurological hazards. Ann Neurol. 1977;46:364–366
  90. Benesova O, Pavlik A. Perinatal treatment with glucocorticoids and the risk of maldevelopment of the brain. Neuropharmacology. 1989;28:89–97
  91. Flagel SB, Vazquez DM, Watson SJ, Neal CR. Effects of tapering neonatal dexamethasone on rat growth, neurodevelopment, and stress response. Am J Physiol Regul Integr Comp Physiol. 2002;282:R55–R63
  92. Baud O, Verney C, Evrard P, Gressens P. Injectable dexamethasone administration enhances cortical GABAergic neuronal differentiation in a novel model of postnatal steroid therapy in mice. Pediatr Res. 2005;57:149–156
  93. Stone DJ, Walsh JP, Sebro R, Stevens R, Pantazopolous H, Benes FM. Effects of pre- and postnatal corticosterone exposure on the rat hippocampal GABA system. Hippocampus. 2001;11:492–507
  94. Shi B, Rabin SJ, Brandoli C, Mocchetti I. Dexamethasone induces hypertrophy of developing medial septum cholinergic neurons: potential role of nerve growth factor. J Neurosci. 1998;18:9326–9334

PII: S1744-165X(07)00026-1

doi: 10.1016/j.siny.2007.01.025

Seminars in Fetal & Neonatal Medicine
Volume 12, Issue 4 , Pages 273-279 , August 2007

Article Tools